The board of directors of Cantargia has resolved to carry out a directed new issue of 16,698,789 shares at a subscription price of SEK 3.55 per share.

The Directed Share Issue will provide Cantargia with approximately SEK 59.3 million before deduction of transaction costs.

Investors in the Directed Share Issue represent a variety of Swedish and international investors including certain existing shareholders, notably the Fourth Swedish National Pension Fund (AP4), the First Swedish National Pension Fund (AP1) and Alecta Tjänstepension.

“The results we have generated and presented for nadunolimab are very promising and highlight its great potential to become a key treatment option in several different cancer forms. It is very positive that with the help of this transaction we now secure our continued preparative work for the phase 2b study in pancreatic cancer and obtain liquidity to drive the company projects into 2025. We are very motivated and grateful for the trust from our investors,” says Göran Forsberg, CEO of Cantargia.

Photo of Göran Forsberg: Håkan Sandbring/Cantargia